NCT01960842View on ClinicalTrials.gov

A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Advanced Parkinson's Disease

Interventions

DRUG

Levodopa-carbidopa intestinal gel

Dose levels will be individually optimized. Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)

DEVICE

CADD-Legacy® 1400 ambulatory infusion pump

DEVICE

PEG tube

percutaneous endoscopic gastrostomy tube

DEVICE

J-tube

jejunal tube